GlassScriptPhysician profile
Bhavin P Patel
NPI 1750379913
$11,263.87
in general payments reported to CMS, 2019-2025
34 companies · $1,972 in 2025
The $1,972 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,847 · 2020: $599 · 2021: $1,310 · 2022: $1,773 · 2023: $1,866 · 2024: $1,897 · 2025: $1,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,521 · Honoraria: $175 · Consulting Fee: $21.42 · Education: $17.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,521.13 |
| Honoraria | $175.00 |
| Consulting Fee | $21.42 |
| Education | $17.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,776.98 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,795.60 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,186.65 | 2019-2025 | |
| Glaxosmithkline, LLC. | $675.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genentech USA, INC. | $625.07 | 2019-2023 | Xolair |
| Alk-Abello, INC | $468.99 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Pfizer INC. | $466.40 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $380.95 | 2020-2025 | Hyqvia, Eohilia |
| Novartis Pharmaceuticals Corporation | $360.21 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.61 | 2019-2023 | Spiriva Respimat |
| Ars Pharmaceuticals Operations, INC. | $269.35 | 2025 | Neffy |
| Amgen INC. | $251.03 | 2022-2025 | Tezspire |
| Aimmune Therapeutics, INC. | $216.10 | 2020-2023 | |
| Genentech, INC. | $186.24 | 2022-2024 | Xolair |
| Csl Behring | $186.18 | 2024-2025 | Andembry, Haegarda |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $175.60 | 2019 | |
| Kaleo, INC. | $168.65 | 2022-2024 | Auvi-Q |
| Grifols Shared Services North America, INC. | $113.41 | 2024 | Xembify |
| Grifols USA, LLC | $100.69 | 2019-2024 | Xembify |
| Shire North American Group INC | $69.28 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $68.86 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $59.99 | 2022 | |
| Sunovion Pharmaceuticals INC. | $59.49 | 2019 | |
| Abbvie INC. | $36.50 | 2022 | |
| Philips North America LLC | $30.92 | 2021-2022 | |
| Optinose US, INC. | $27.13 | 2020-2022 | |
| Blueprint Medicines Corporation | $22.92 | 2023 | Ayvakit |
| Integra Lifesciences Corporation | $22.20 | 2024 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Adma Biomanufacturing LLC | $21.42 | 2023 | |
| Merck Sharp & Dohme LLC | $20.93 | 2023 | |
| Jubilant Hollisterstier LLC | $19.35 | 2024 | |
| Lilly USA, LLC | $16.49 | 2025 | Ebglyss |
| Leo Pharma INC. | $14.26 | 2022 | |
| Horizon Therapeutics Plc | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhavin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.